Avoid turning endometriosis into a reason for over-medicalization
Nearly 190 million women worldwide live with endometriosis, and for those who become pregnant, clinical uncertainty has long shadowed what should be a period of careful but measured care. A French panel of 23 obstetric specialists, publishing their findings in May 2026, has now offered a reasoned answer to that uncertainty: in most cases, standard prenatal surveillance is sufficient, and the reflex to classify endometriosis as an automatic high-risk condition does more to generate anxiety than to improve outcomes. Their work is a reminder that in medicine, as in life, the impulse to do more is not always the same as the wisdom to do what is needed.
- For decades, clinicians managing pregnant women with endometriosis had no shared standard of care, leaving a vacuum filled by precaution, inconsistency, and unnecessary alarm.
- A structured Delphi process involving 23 French obstetric specialists systematically reviewed the evidence across nine clinical domains, separating theoretical risk from measurable clinical reality.
- The most striking finding cuts against common assumption: elevated risks for hypertension and fetal growth restriction, long cited as concerns, proved negligible or manageable within routine prenatal monitoring.
- One genuine outlier emerged — placenta previa carries a sixfold increase in risk among women with endometriosis, and postpartum hemorrhage risk rises 1.76-fold, warranting active management of the third stage of labor.
- The consensus lands as a call for individualized care over automatic escalation, while honestly acknowledging that observational study limitations and the heterogeneity of endometriosis itself leave important evidence gaps still to be filled.
A panel of 23 French obstetric specialists has concluded that pregnant women with endometriosis do not, in most cases, require intensified monitoring — a finding that pushes back against the clinical instinct to treat the condition as automatically high-risk. Published in May 2026 in the European Journal of Obstetrics & Gynecology and Reproductive Biology, the consensus emerged from a modified Delphi process: two rounds of structured surveys, a systematic review of PubMed and Cochrane literature, and an in-person meeting in March 2024, with evidence graded using the GRADE system.
Endometriosis affects roughly 10 percent of reproductive-age women — nearly 190 million people worldwide — causing tissue similar to the uterine lining to grow outside the uterus, often producing pain and infertility. Pregnancy can temporarily ease symptoms through a process called decidualization, but clinicians have long worried about elevated risks for premature birth, preeclampsia, and placenta previa. The problem was that no standard management approach existed, and no one had rigorously tested whether aggressive surveillance actually improved outcomes.
What the panel found was clarifying. For hypertension, higher-quality studies showed odds ratios of just 1.04 to 1.08 — no meaningful elevation — and standard monthly blood pressure checks were deemed sufficient. For fetal growth, while small-for-gestational-age births appeared modestly more common, routine ultrasounds at 12, 22, and 32 weeks remained adequate. Premature birth showed a more real signal, with odds ratios between 1.49 and 1.70, yet no evidence supported progesterone or bed rest as preventive interventions in this population.
Two risks did warrant specific attention. Placenta previa showed a striking sixfold increase among women with spontaneous pregnancies and endometriosis, though the panel stopped short of recommending additional transvaginal ultrasounds beyond routine screening. Postpartum hemorrhage risk rose 1.76-fold, and here the panel made its clearest intervention: active management of the third stage of labor. Early hormonal contraception, begun within two months of delivery, was also endorsed to slow the return of endometriosis symptoms.
The consensus carries an implicit ethical argument — that a diagnosis of endometriosis should not automatically reclassify a woman as high-risk when her pregnancy is otherwise uncomplicated. The panel was equally candid about what remains unknown: most underlying studies were observational, vulnerable to confounding from assisted reproduction or adenomyosis, and rarely distinguished between superficial, ovarian, and deeply infiltrating forms of the disease. What they offered was not a final word, but a reasoned framework: standard vigilance, targeted attention to specific risks, and resistance to the assumption that complexity always demands intensity.
A French panel of 23 obstetric specialists has concluded that pregnant women with endometriosis do not require intensified monitoring in most cases—a finding that pushes back against the instinct to treat the condition as automatically high-risk. The consensus, published in May 2026 in the European Journal of Obstetrics & Gynecology and Reproductive Biology, emerged from a structured expert process that examined nine clinical domains and reviewed the actual evidence behind common assumptions about how endometriosis affects pregnancy.
Endometriosis is a chronic inflammatory condition that touches roughly 10 percent of women of reproductive age—nearly 190 million people worldwide. The disease causes tissue similar to the uterine lining to grow outside the uterus, often triggering pain and infertility. Pregnancy itself can sometimes improve symptoms temporarily, as the lesions undergo a process called decidualization. Yet for decades, clinicians have worried that endometriosis might increase the risk of serious complications: premature birth, preeclampsia, placenta previa. The problem was that no one had settled on a standard way to manage these pregnancies, leaving doctors uncertain whether aggressive surveillance actually improved outcomes or simply created unnecessary anxiety.
The panel, drawn from 21 French university hospital centers, used a modified Delphi methodology—two rounds of structured online surveys followed by an in-person consensus meeting in March 2024. They systematically reviewed the literature on PubMed and Cochrane, then graded the strength of evidence using the GRADE system. What they found was sobering in its clarity: the theoretical risks did not always match the clinical reality. For hypertension, while some older analyses suggested a modest increase in risk, higher-quality studies showed odds ratios of 1.04 to 1.08—essentially no meaningful elevation. The panel recommended standard monthly blood pressure checks, nothing more. For fetal growth, small-for-gestational-age babies did appear somewhat more common in women with endometriosis, but the panel saw no reason to add ultrasounds beyond the routine three at 12, 22, and 32 weeks.
Premature birth presented a trickier picture. Observational studies reported odds ratios between 1.49 and 1.70, suggesting a real increase in risk. Yet there was no evidence that giving progesterone or recommending bed rest actually prevented early delivery in this population. The panel could not recommend interventions for which no benefit had been shown. One finding did stand out: placenta previa, the condition in which the placenta covers the cervix, showed a striking sixfold increase in risk among women with spontaneous pregnancies and endometriosis. Even so, the panel did not recommend extra transvaginal ultrasounds beyond routine screening. The one intervention the panel did endorse was active management of the third stage of labor—the delivery of the placenta—to reduce postpartum hemorrhage risk, which carried a 1.76-fold increase.
The consensus carries an implicit message: avoid turning endometriosis into a reason for over-medicalization. A woman with endometriosis and a straightforward pregnancy should not automatically be reclassified as high-risk simply because of her diagnosis. Instead, the panel advocated for individualized care that maintains standard vigilance for blood pressure and fetal growth, watches carefully for signs of placenta previa, and ensures active management of the third stage of labor. Early hormonal contraception—started within two months after delivery—can also help prevent the rapid return of endometriosis symptoms.
Yet the consensus also exposed significant gaps in the evidence base. Most studies were observational, vulnerable to confounding factors like assisted reproductive technology use or the presence of adenomiosis, a related condition affecting the uterine muscle. The heterogeneity of endometriosis itself—superficial, ovarian, or deeply infiltrating forms—is rarely distinguished in research, making it hard to tailor recommendations for the most severe cases. The panel acknowledged these limitations frankly. What they offered was not a final answer but a reasoned framework: standard care, targeted attention to specific risks, and resistance to the assumption that complexity always demands intensity.
Citas Notables
Endometriosis isolada não deve ser motivo para transformar um pré-natal de risco habitual em pré-natal de alto risco— Consensus panel recommendation
La Conversación del Hearth Otra perspectiva de la historia
Why did the panel feel compelled to push back against intensified monitoring? Wasn't that the safer approach?
Because safety isn't just about doing more. Over-medicalization creates its own harms—unnecessary anxiety, more interventions, more chances for things to go wrong. The panel looked at the actual data and found that for most complications, the increased risk was either small or unproven to respond to extra surveillance.
But placenta previa showed a sixfold increase. That's substantial. Why not screen more aggressively for that?
It is substantial, and they did flag it as something to watch for. But they found no evidence that extra ultrasounds caught it earlier or changed the outcome. The condition is already screened at routine visits. Adding more imaging doesn't seem to help.
What about the women with severe, deeply infiltrating endometriosis? Does this consensus apply to them equally?
That's the honest gap. The studies don't consistently separate the different forms of endometriosis, so the panel couldn't make specific recommendations for the worst cases. They acknowledged that limitation directly.
So the message is essentially: treat endometriosis in pregnancy like you would any other pregnancy, but stay alert?
Exactly. Standard care, individualized attention, and resistance to the reflex to classify someone as high-risk just because of a diagnosis. It's a more nuanced approach than either extreme.
What about after the baby is born? Does endometriosis management change?
Yes. They recommend starting hormonal contraception within two months postpartum to prevent the disease from flaring up again quickly. That's one concrete intervention that does have evidence behind it.